Class 4 caution in use-Lansoprazole 15mg hard caps Teva

Teva UK Limited is reporting a minor typographical error on the carton for Lansoprazole Gastro-Resistant Hard Capsules 15mg. There are two instances where the dosage form is stated as “tablets” where it should state “gastro-resistant capsule, hard”.

MHRA Drug alert date: 11th February 2025

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-lansoprazole-gastro-resistant-hard-capsules-15mg-el-25-a-slash-06?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=0d2bb3ae-b928-4794-a36a-408d0f4fb540&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please telephone 0207 540 7117 or email medinfo@tevauk.com.

For stock control enquiries telephone 0800 590502 or email Customer.services@tevauk.com.

Class 2 recall- Nitrofurantoin 100 mg Prolonged-Release capsules

Class 2 recall- Nitrofurantoin 100 mg Prolonged-Release capsules

CNX Therapeutics is recalling the batches listed in this notification as a precautionary measure due to a small number of packs that contain an additional tablet of Nitrofurantoin. The registered product is a capsule containing powder and two yellow tablets.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-nitrofurantoin-cnx-therapeutics-100-mg-prolonged-release-capsules-el-25-a-slash-05?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=1ea315d7-385a-456b-af14-f9e50bb7568c&utm_content=immediately

MHRA ref: DMRC-34425982

Further information

For medical information enquiries please contact 0207 821 2840 or medinfo@cnx-therapeutics.com

For stock control enquiries please contact 0207 821 2840 or supplychain@cnx-therapeutics.com

Please return all affected stock to your original supplier for credit.

Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited).

Please note that anything not returned to us, or notified to us, within 12 weeks of this notification, cannot be reimbursed by way of a credit.

Class 2 recall-Amlodipine 2.5mg tablets Bristol

Bristol Laboratories Limited is recalling the batches specified in the table as a precautionary measure due to possible microbial contamination.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-bristol-laboratories-limited-amlodipine-bristol-lab-2-dot-5-mg-tablets-el-25-a-slash-04?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=3a7e5e7f-ca74-4fe6-9005-c90bbe44a2d0&utm_content=immediately

Further information

For medical information enquiries please contact: Notifications@bristol-labs.co.uk

For stock control enquiries please contact: Notifications@bristol-labs.co.uk

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited).

Please note that anything not returned to us, or notified to us, within 12 weeks of this notification, cannot be reimbursed by way of a credit.

Class 2 Recall - ALMUS DRY COUGH RELIEF 200ML

CLASS 2 RECALL

Bells Healthcare Limited on ALMUS DRY COUGH RELIEF 200ML

• MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-tesco-health-dry-cough-relief-200ml-asda-strong-dry-tickly-cough-200ml-almus-dry-cough-relief-and-bells-dual-action-dry-cough-el-25-a-slash-03?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e435ef37-e02b-4503-bf1b-66b46e4dabfd&utm_content=immediately

• MHRA ref: DMRC-34222471

Further information

For medical information enquiries please contact: Trevor Price, QPPV, trevor.price@bells-healthcare.com

For stock control enquiries please contact: Chris Bracken chris.bracken@bells-healthcare.com

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited).

Please note that anything not returned to us, or notified to us, within 12 weeks of this notification, cannot be reimbursed by way of a credit.

Alliance Healthcare will only be accepting  returns against the Almus livery that we stock.

Class 4 caution in use-Irbesartan 150mg & 300mg Tablets

Jubilant Pharmaceuticals NV has informed the MHRA that the Patient information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.

MHRA Drug alert date: 13th January 2025

MHRA Drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-irbesartan-150-mg-and-300-mg-film-coated-tablets-el-25-a-slash-02?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=ba29731f-c857-4e43-9347-5e2d5baeafc8&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact: safety.uk@lambda-cro.com, Telephone number: 0080089013370

For stock control enquiries please contact: JPUK.Customerservice@jubl.com, Telephone: +4401233 552293

Class 4 caution in use-Rabeprazole sodium 10 & 20mg GR tablets

Bristol Laboratories Limited has informed the MHRA that the Patient Information Leaflet (PIL) in the batches in the table for Rabeprazole sodium 10mg and 20mg gastro-resistant tablets do not contain the most up to date safety information.

MHRA Drug alert date: 9th January 2025

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-rabeprazole-sodium-10mg-and-20mg-gastro-resistant-tablets-el-25-a-slash-01?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=2ea2f68a-a589-4a59-9548-7c91851e5608&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact at: email: info@bristol-labs.co.uk, or telephone: +44 (0) 1442 200 922

For stock control enquiries please contact at email: notifications@bristol-labs.co.uk, or telephone: +44 (0) 1442 200 922

Class 4 caution in use-Vyvgart 1000mg solution for injection

Argenx BV have informed MHRA that the Patient Information Leaflet (PIL) in the affected packs incorrectly contains reference to two subcutaneous injection sites. Only subcutaneous injection to the abdomen is permitted.

MHRA Drug alert date: 19th December 2024

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-argenx-bv-vyvgart-1000-mg-solution-for-injection-el-24-a-slash-63?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=ab2d5607-6db9-4cc3-9766-16136bc8802d&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact ukmedinfo@argenx.com or +44 (0)20 4532 4016.

For stock control enquiries please contact rpi@argenx.com or +44 (0)7801 748936.

Field Safety notice-Various AMS dressings

We have received a field safety notice from Advanced Medical Solutions (AMS) regarding batches of various dressings

Date of recall:17/12/24

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 2 Recall-WockAIR 160 microgram/4.5 microgram, inhalation powder

Wockhardt UK Limited is recalling this batch as a precautionary measure following the identification of a low number of units which may have a defect in the 'top case' resulting in a dose not being able to be dispensed.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-wockhardt-uk-limited-wockair-160-microgram-slash-4-dot-5-microgram-inhalation-powder-el-24-a-slash-62?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=196509da-279d-4663-b40b-c3c0cadad8aa&utm_content=immediately

Further information

For medical information enquiries please telephone 01978 661261 and ask for ‘drug safety’, or email drug.safety@wockhardt.co.uk.

For stock control enquiries please telephone 01978 661261 and ask for ‘customer services’, or email group_uk_csu@wockhardt.co.uk.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited).

Please note that anything not returned to us, or notified to us, within 12 weeks of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Liothyronine Sodium tablets 5mcg and 20mcg

Strides Pharma UK Ltd has informed MHRA of an error in the patient information leaflet (PIL) for Liothyronine Sodium 20 micrograms Tablets and Liothyronine Sodium 5 micrograms Tablets.

MHRA Drug alert date: 28th November 2024

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-strides-pharma-uk-ltd-liothyronine-sodium-5-and-20-micrograms-tablets-el-24-a-slash-58?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=1b6cc57b-c4b2-4d42-b911-de0ebf43fd1b&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact Strides Pharma UK Ltd via email dl-drugsafety@strides.com or telephone +919844460742

For stock control enquiries please contact Strides Pharma UK Ltd via email customerservicesuk@stridespharma.co.uk or telephone 01923 255580